Boston Scientific Q3 Sales Up 1.5% to $5.14B; Q4 Sales Guided Down 1-3%
BSX is trading near its 52-week low of $41.385 (3.5% above the low).
Summary
Boston Scientific reported Q3 2026 sales of $5.138 billion, up 1.5%, with adjusted EPS of $0.73 versus $0.75 a year ago. Q4 sales are guided down 1-3%, and full-year adjusted EPS to $3.16-$3.18, as the August cyberattack continues to weigh on operations.
Key Events · Earnings and Guidance · BSX
-
Q3 Sales Grow Only 1.5%
Net sales of $5.138 billion rose 1.5% on a reported, operational and organic basis versus $5.065 billion a year ago. Neuromodulation grew 13.1%, while Urology fell 3.2% and Endoscopy 0.8%.
-
Adjusted EPS Slips to $0.73
GAAP EPS fell to $0.40 from $0.51 and adjusted EPS to $0.73 from $0.75, with litigation-related net charges of $81 million and restructuring charges of $63 million weighing on the quarter.
-
Q4 Guidance Calls for Sales Decline
Management expects Q4 2026 net sales to decline approximately 3.0% to 1.0% on a reported and organic basis, with adjusted EPS of $0.77 to $0.79.
-
Full-Year EPS Guided to $3.16-$3.18
Full-year 2026 net sales growth is estimated at approximately 4.25% reported and 3.75% organic, with adjusted EPS of $3.16 to $3.18.
Analysis · BSX · Industrial Applications And Services
The cyberattack's damage now has a number attached: sales grew just 1.5% to $5.138 billion, adjusted EPS slipped to $0.73 from $0.75, and GAAP EPS fell to $0.40 from $0.51. The forward view matters more. Management expects Q4 sales to fall 1% to 3% year over year, a sharp reversal from the growth investors had been paying for, and full-year adjusted EPS of $3.16-$3.18 sits below the prior trajectory. With the stock already near its 52-week low, the guidance confirms a slower operational recovery rather than a one-quarter blip.
How filings like this one have moved
In the 30 days to Oct 28, 2026, 36.5% of the 953 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.66%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, BSX was trading at $42.85 on NYSE in the Industrial Applications And Services sector, with a market capitalization of approximately $65.3B. The 52-week trading range was $41.39 to $105.65. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.